Incannex Healthcare Inc. - Common Stock (IXHL)
0.8610
+0.0310 (3.73%)
Incannex Healthcare Inc. is a biotechnology company focused on developing innovative therapies that harness the potential of cannabinoid-based medicine
The company is dedicated to conducting rigorous clinical research to create safe and effective treatments for a range of medical conditions, including pain, anxiety, and other illnesses. Incannex aims to navigate the evolving regulatory landscape and collaborate with medical professionals to bring cannabinoid solutions to patients, while also emphasizing the importance of scientific validation and patient safety in the pharmaceutical field.
Previous Close | 0.8300 |
---|---|
Open | 0.8100 |
Bid | 0.8600 |
Ask | 0.9200 |
Day's Range | 0.8000 - 1.180 |
52 Week Range | 0.7300 - 3.630 |
Volume | 422,199 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 44,974 |
News & Press Releases
Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on...
Via Newsfile · February 18, 2025
Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate...
Via Newsfile · December 2, 2024

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via Investor's Business Daily · November 15, 2024
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on...
Via Newsfile · October 2, 2024

Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.
Via Benzinga · September 10, 2024
New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a...
Via Newsfile · September 9, 2024

FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application.
Via Benzinga · August 5, 2024

We have the biggest pre-market stock movers that investors are going to want to start the trading week with on Monday morning!
Via InvestorPlace · July 1, 2024

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Via InvestorPlace · June 27, 2024

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.
Via Benzinga · May 7, 2024
Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to...
Via Newsfile · May 1, 2024

Via Benzinga · April 17, 2024

The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via Talk Markets · April 12, 2024

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via Talk Markets · March 30, 2024

Via Benzinga · March 29, 2024

Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. Heroic Hearts Project supports veterans with PTSD through legal psychedelic therapy. Colorado's Natural Medicine Health Act is a model for integrating psychedelics into public health.
Via Benzinga · March 22, 2024

Via Benzinga · March 20, 2024

The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via Talk Markets · March 11, 2024

Via Benzinga · March 4, 2024

The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via Talk Markets · March 1, 2024

Via Benzinga · February 28, 2024

Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.
Via Benzinga · February 28, 2024

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via Benzinga · February 28, 2024

In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples.
Via Talk Markets · February 25, 2024

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.
Via Talk Markets · February 18, 2024